Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors in Oncology Clinical Trials: A review
Journal of Immunotherapy and Precision Oncology · 01.08.2022 · 5 (3) · 58-67
DOI: 10.36401/jipo-22-1 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Immunotherapy and Precision Oncology, online erschienen am 22.06.2022. Verfasst von Kavanya Feustel und 1 weiteren Autor:innen. Beteiligte Einrichtung: Sky Ridge Medical Center, HCA Continental Division, Lone Tree, CO, USA. Die Arbeit wurde bisher 145-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Protein arginine methyltransferase 5 (PRMT5) inhibitors are a new class of antineoplastic agents showing promising preliminary clinical efficacy. Targeting an enzyme involved in a wide array of cellular and transcriptional pro-oncogenic processes, this class offers multifaceted tumor-suppressive effects. Partial response has been seen in adenoid cystic carcinoma from both GSK3326595 and JNJ-64619178, with four cases of stable disease seen with PRT543. Highly significant is a durable complete response in isocitrate dehydrogenase 1-mutated glioblastoma multiforme with PRT811. Both alone and in combination with existing chemotherapies and immunotherapies, this class shows promising preliminary data, particularly in cancers with splicing mutations and DNA damage repair deficiencies. Further studies are warranted, and there are clinical trials to come whose data will be telling of the efficacy of PRMT5 inhibitors in both hematologic and solid malignancies. The aim of this study is to compile available results of PRMT5 inhibitors in oncology clinical trials.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Sky Ridge Medical Center, HCA Continental Division, Lone Tree, CO, USA.
- Sarah Cannon Research Institute at HealthOne, Denver, CO, USA.
Zitieren
APA
Feustel, K., & Falchook, G. S. (2022). Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors in Oncology Clinical Trials: A review. Journal of Immunotherapy and Precision Oncology, 5(3), 58-67. https://doi.org/10.36401/jipo-22-1
Vancouver
Feustel K, Falchook GS. Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors in Oncology Clinical Trials: A review. Journal of Immunotherapy and Precision Oncology. 2022;5(3):58-67. doi:10.36401/jipo-22-1
BibTeX
@article{Feustel2022,
author = {Feustel, Kavanya and Falchook, Gerald S},
title = {Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors in Oncology Clinical Trials: A review},
journal = {Journal of Immunotherapy and Precision Oncology},
year = {2022},
volume = {5},
number = {3},
pages = {58--67},
doi = {10.36401/jipo-22-1}
}
EUVIMED